Publicaciones en colaboración con investigadores/as de Hospital del Mar (22)

2023

  1. Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis

    Clinical and Translational Oncology, Vol. 25, Núm. 4, pp. 941-958

2021

  1. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study

    European Journal of Cancer, Vol. 156, pp. 70-82

  2. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID-19 Pandemic in Spain

    Oncologist, Vol. 25, Núm. 9, pp. e1339-e1345

  2. Phase Ia study of anti-NAPI2B antibody–drug conjugate lifastuzumab vedotin DNIB0600A in patients with non–small cell lung cancer and platinum-resistant ovarian cancer

    Clinical Cancer Research, Vol. 26, Núm. 2, pp. 364-372

2018

  1. Balixafortide (a novel CXCR4 inhibitor) and eribulin in HER2-neg metastatic breast cancer (MBC) patients (pts): A phase I trial

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii91-viii92

  2. Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy

    Oncotarget, Vol. 9, Núm. 41, pp. 26406-26416

2017

  1. Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2- negative breast cancer

    Oncotarget, Vol. 8, Núm. 13, pp. 21930-21937

2016

  1. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: Results from a phase Ib/IIa study

    Annals of Oncology, Vol. 27, Núm. 7, pp. 1249-1256

  2. Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature

    Critical Reviews in Oncology/Hematology, Vol. 97, pp. 96-106

2015

  1. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: Long-term results of the Spanish GCR-3 phase II randomized trial

    Annals of Oncology, Vol. 26, Núm. 8, pp. 1722-1728

  2. Population-based multicase-control study in common tumors in Spain (MCC-Spain): Rationale and study design

    Gaceta Sanitaria, Vol. 29, Núm. 4, pp. 308-315

  3. Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer

    Current Medical Research and Opinion, Vol. 31, Núm. 6, pp. 1129-1137

2014

  1. Predicting response and survival in chemotherapy-treated triple-negative breast cancer

    British Journal of Cancer, Vol. 111, Núm. 8, pp. 1532-1541

2013

  1. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: Results from the GEICAM/2003-02 study

    Journal of Clinical Oncology

2011

  1. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials

    The Lancet, Vol. 378, Núm. 9793, pp. 771-784

2010

  1. Current controversies in the management of breast cancer

    Clinical and Translational Oncology, Vol. 12, Núm. 4, pp. 278-286

  2. Erratum: Current controversies in the management of breast cancer (Clinical and Translational Oncology 12:4 (278-286))

    Clinical and Translational Oncology

  3. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast

    Journal of the National Cancer Institute - Monographs, Vol. 41, pp. 162-177

2008

  1. Time-to-progression in breast cancer: A stratification model for clinical trials

    Breast, Vol. 17, Núm. 3, pp. 239-244